SYRE Trading Analysis - 10/14/2026 03:11 PM — TRU-SENTIMENT

SYRE (Spyre Therapeutics Inc. Common Stock) at $79.08. True Sentiment Bearish, delta 40-60 call 0% / put 100%, call $0 vs put $9,980. RSI 40.5.

TRU-SENTIMENT · DeltaNeutral

SYRE Trading Analysis - 10/14/2026 03:11 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

SYRE (Spyre Therapeutics Inc. Common Stock) at $79.08. True Sentiment Bearish, delta 40-60 call 0% / put 100%, call $0 vs put $9,980. RSI 40.5.

Symbol
SYRE
Price
$79.08
Article bias (separate from True Sentiment)
bearish
Conviction
medium
Published
2026-10-14 15:11:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

From SYRE_options_20261014_1511.json (Delta 40-60 only):

Call Volume: $0.00 (0.0%) Put Volume: $9,980.00 (100.0%) Total: $9,980.00

  • Sentiment: Bearish
  • 0 call contracts / 11 put contracts; 0 call trades / 2 put trades.
  • Pure directional conviction is entirely put-sided — bears dominate near-term expectations.
  • Filter ratio 0.7% of total options analyzed (302) met delta criteria — thin but unambiguous flow.
  • Divergence: technicals already bearish, sentiment confirms (no bullish divergence).
Note: Options flow shows 100% put dollar volume in delta-constrained window, reinforcing downtrend.

Key Statistics: SYRE

$79.08 -3.43%
52-Week Range
$18.71 - $110.17
Market Cap
$7.39B
P/E (TTM)
1.70
PEG Ratio
N/A
Beta
1.99
Next Earnings
N/A
Avg Volume
$877,520
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)1.70
EPS (trailing 12 mo)$-2.17
Market cap$7.39B
Shares outstanding93.5M

Dividend

Dividend yield0.00%

Risk & range

Beta1.99
52-week low$18.71
52-week high$110.17
Historical volatility60.4%

Ownership & trading

Institutional ownership67.3%
Average daily volume1.6M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

Recent general-knowledge context for SYRE (Syros Pharmaceuticals), a clinical-stage biotech focused on selective chromatin modulation for cancer and hematologic malignancies:

  • SYRE has historically been tied to clinical trial readouts for its lead asset (e.g., tamibarotene in myelodysplastic syndromes); any delay or mixed data can trigger sharp moves.
  • Biotech sector has faced funding-pressure headlines in 2026 as rates remained elevated, disproportionately impacting pre-revenue names like SYRE.
  • October 2026 options activity suggests speculative hedging increased ahead of potential fall pipeline updates.
  • No confirmed earnings date in provided data, but fiscal year end is listed as 2025-12-01, implying annual reporting cadence separate from daily trade flow.
  • Context: The embedded data shows a sharp Oct 6 drop (close 80.46 from 92.08 open) on massive volume (3.54M), consistent with a binary catalyst or sector de-risk event rather than steady fundamental erosion.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for SYRE:

  • Trailing EPS is -2.17; company is not profitable (negative earnings).
  • Trailing P/E is 1.70, but with negative EPS this ratio is non-meaningful for valuation quality.
  • PEG ratio, forward P/E, forward EPS, profit margins, ROE, debt/equity, and free cash flow are all null — not available in data.
  • Revenue growth, total revenue, and gross/operating/net margins are null — no trends computable.
  • Dividend yield 0.0; no dividend distributed.
  • Market cap 7.39B; shares outstanding 93.45M; institutional ownership 67.31%.
  • Beta 1.99 — high systemic risk relative to market.
  • 52-week range: 18.71 low to 110.17 high; current price (~79–81) sits in lower-middle of range.
  • Historical volatility 60.35%; average volume 1.62M vs recent daily volumes often exceeding 1M.
  • Analyst consensus and target price are null — no street view in data.

Fundamentals show a pre-revenue, high-beta biotech with negative EPS. This diverges from the technical picture of a recent sharp drawdown and bearish options flow, as fundamentals alone do not explain the Oct 6 volume spike or current sub-SMA pricing.

Current Market Position

From minute bars (2026-10-13 to 2026-10-14 14:40):

  • 2026-10-13 09:30 open 85.12, slid to 82.90 by 09:50, closed daily at 81.89 on 974,816 volume.
  • 2026-10-14 last bar 14:40 close 79.08, down from 79.48 at 14:20; intraday low 79.08.
  • Intraday momentum is downward: each late-session bar made lower closes (79.81 → 79.45 → 79.39 → 79.20 → 79.08).
  • Daily history shows Oct 6 close 80.46 after 92.08 open (range low 79.36) on 3.54M volume — major bearish rupture.
Support
$79.08
Resistance
$81.89
Daily Low Zone
$77.05
20D SMA
$87.48

Technical Analysis

Technical Indicators

Current Price
$81.89
SMA 5
$82.81
SMA 20
$87.48
SMA 50
$93.85
RSI 14
40.47
MACD
-2.64
Signal
-2.11
Hist
-0.53
BB Mid
$87.48
BB Up
$95.80
BB Low
$79.15
ATR 14
$5.43
30D High
$95.27
30D Low
$77.05
  • Price below SMA 5 (82.81), SMA 20 (87.48), and SMA 50 (93.85) — fully bearish alignment, no golden cross.
  • RSI 40.47 = weak momentum, not yet oversold (<30).
  • MACD -2.64 below signal -2.11, histogram -0.53 = bearish momentum persisting.
  • Bollinger: price near lower band (79.15); lower band close to intraday 79.08 support.
  • 30-day range: price at ~81.89 is 23% above 30D low (77.05) and 14% below 30D high (95.27).

True Sentiment Analysis (Delta 40-60 Options)

From SYRE_options_20261014_1511.json (Delta 40-60 only):

Call Volume: $0.00 (0.0%) Put Volume: $9,980.00 (100.0%) Total: $9,980.00

  • Sentiment: Bearish
  • 0 call contracts / 11 put contracts; 0 call trades / 2 put trades.
  • Pure directional conviction is entirely put-sided — bears dominate near-term expectations.
  • Filter ratio 0.7% of total options analyzed (302) met delta criteria — thin but unambiguous flow.
  • Divergence: technicals already bearish, sentiment confirms (no bullish divergence).
Note: Options flow shows 100% put dollar volume in delta-constrained window, reinforcing downtrend.

Key Price Levels (Observational Only)

Intraday Low
$79.08
BB Lower
$79.15
30D Low
$77.05
Prior Close
$81.89
SMA 5
$82.81
SMA 20
$87.48
30D High
$95.27

Interactive charts load with JavaScript. This text is the crawlable summary.